President Joe Biden’s efforts to make prescription drugs more affordable have taken on new significance as he prepares to hand over the presidency to Donald Trump. The Department of Health and Human Services recently announced 15 drugs subject to Medicare’s negotiation power, aiming to lower prices for breakthrough medications like Ozempic and Wegovy.
The reforms are a key part of Biden’s domestic policy legacy, which top officials are using to highlight their achievements in the outgoing administration. However, the new president faces significant challenges in defending these initiatives, particularly with Republicans already vowing to roll back the reforms.
Critics argue that the reforms will lead to fewer breakthroughs by reducing the financial incentive for innovation. Senator Mike Crapo and the Heritage Foundation have expressed plans to repeal the reforms, citing concerns about market dynamics.
Despite this opposition, some experts believe that Trump’s unpredictable feelings on drug pricing might actually work in favor of the reforms. The president has been critical of the pharmaceutical industry and may be more receptive to changes than expected.
Historically, major healthcare initiatives often gain momentum through public awareness and education campaigns. If the public recognizes the importance of preserving these programs, they can help insulate them from opposition. Ultimately, the future of Biden’s prescription drug reforms will depend on the ability of their defenders to rally public support and defend these crucial investments in public health.
Source: https://www.huffpost.com/entry/biden-trump-medicare-prescription-drug-prices_n_678ab2d2e4b0aa5a1d95bb3f